Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049010 · ClinicalTrials.gov registry record · NA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
A NA study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- NA
- Development phase
- 314
- Enrollment target
NCT00049010 is a NA study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 314 participants.
The verdict
NCT00049010, a NA study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- NA
- Development phase
- 314 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures that analyze surgically-removed tumor tissue and lymph node samples may help doctors identify patients with melanoma who are at risk for developing metastatic cancer. PURPOSE: This clinical trial is studying tumor tissue and lymph node samples to see how well they work in predicting the development of metastatic cancer in patients with stage I or stage II melanoma.
Interventions
- OTHER immunohistochemistry staining method
- GENETIC cytogenetic analysis
- GENETIC fluorescence in situ hybridization
- GENETIC comparative genomic hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2002-09 |
| Est. Completion | 2009-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049010
The ClinicalTrials.gov registry entry for NCT00049010 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which immunohistochemistry staining method is the first listed.
NCT00049010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049010 about?
NCT00049010 is a clinical study titled "Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma". RATIONALE: Diagnostic procedures that analyze surgically-removed tumor tissue and lymph node samples may help doctors identify patients with melanoma who are at risk for developing metastatic cancer. PURPOSE: This clinical trial is studying tumor tissue and lymph node samples to see how well they w...
What is the current status of trial NCT00049010?
This trial is currently completed. It is a NA study. The enrollment target is 314 participants. The study started on 2002-09. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00049010?
The interventions under investigation include: immunohistochemistry staining method (OTHER), cytogenetic analysis (GENETIC), fluorescence in situ hybridization (GENETIC), comparative genomic hybridization (GENETIC).
Who is sponsoring clinical trial NCT00049010?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.